Cargando…
Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population
Propafenone is an antiarrhythmic drug metabolized primarily by cytochrome P450 2D6 (CYP2D6). In adults, propafenone adverse events (AEs) are associated with CYP2D6 poor metabolizer status; however, pediatric data are lacking. Subjects were tested for 10 CYP2D6 allelic variants and copy number status...
Autores principales: | Sunthankar, Sudeep D., Kannankeril, Prince J., Gaedigk, Andrea, Radbill, Andrew E., Fish, Frank A., Van Driest, Sara L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283732/ https://www.ncbi.nlm.nih.gov/pubmed/35514162 http://dx.doi.org/10.1111/cts.13296 |
Ejemplares similares
-
Pediatric CYP2D6 metabolizer status and post‐tonsillectomy nausea and vomiting after ondansetron
por: Black, Katherine, et al.
Publicado: (2022) -
Propafenone and propranolol dual toxicity
por: Farooq, Moonis, et al.
Publicado: (2020) -
CYP2D6 genotype and adverse events to risperidone in children and adolescents
por: Oshikoya, Kazeem A., et al.
Publicado: (2019) -
The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis
por: Tran, Quyen Thi, et al.
Publicado: (2022) -
Proarrhythmia Induced by Propafenone: What is the Mechanism?
por: Femenia, Francisco, et al.
Publicado: (2010)